Jan

2012

Excelimmune, Inc.: Series C $12M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, X - Oncology, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Jan

2012

Affinium Pharmaceuticals, Inc.: Series B $15M

Posted in I - Series B, Q - 3Q11, R - SOUTH WEST, X - Antibacterial, X - Antiinfective, X - MRSA, XX - TX

Affinium Pharmaceuticals (Austin, TX) a clinical-stage specialty pharmaceutical company focused on small molecule antibiotics targeting staph and MRSA infections, closed a $15M Series B financing. Participants include SV Life Sciences, Genesis Capital Partners, Forward Ventures and Ontario Emerging Technologies Fund.
Thanx for your patience as we catch-up.

Jul

2011

Excelimmune, Inc.: Series B $10.5M

Posted in I - Series B, Q - 2Q11, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $10.5M Series B financing. Participants were not identified.

May

2011

Rib-X Pharmaceuticals, Inc.: Series E $20M

Posted in I - Series E, Q - 1Q11, R - NORTH EAST, X - Antiinfective, X - Bronchitis, X - MRSA, X - Pneumonia, XX - CT

Rib-X Pharmaceuticals (New Haven, CT) a clinical-stage small molecule drug discovery company developing antiinfectives against community acquired pneumonia, chronic bronchitis and complicated skin infections, closed a $20M Series E financing. Participants have included Warburg Pincus, ABS Ventures, Axiom Ventures, EuclidSR Partners, MedImmune Ventures, Oxford Bioscience Partners, SR One and Vox Equity Partners.

Oct

2010

ExcelImmune, Inc.: Series A $4.5M

Posted in I - Series A, Q - 3Q10, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $4.5M Series A financing. Participants were not identified.

Jul

2010

Molecular Detection, Inc.: Series C $1.4M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Device (Diagnostic), X - MRSA, XX - PA

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

Jan

2010

Nabriva Therapeutics, AG: Series B $22M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Antiinfective, X - MRSA

Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Dec

2009

Molecular Detection, Inc.: Series C $3.3M

Posted in I - Series C, Q - 4Q09, R - NORTH EAST, X - Device (Diagnostic), X - MRSA, XX - PA

Molecular Detection (Wayne, PA) a development-stage molecular diagnostics company focused on reat-time PCR of MRSA detection, closed a $3.3M Series C financing. Participants include MentorTech Ventures, Ben Franklin Technology Partners, Robin Hood Ventures and the Mid-Atlantic Angel Group.

Oct

2009

AdvanDx, Inc.: Series C $8M

Posted in I - Series C, Q - 3Q09, R - NORTH EAST, X - Device (Diagnostic), X - MRSA, X - S. aureus, XX - MA

AdvanDx (Woburn, MA) a commercial-stage molecular diagnostics company focused on MRSA, Stap aureus and enterococci assays, closed a $8M Series C financing. Participants include SLS Venture and LD Pensions.

Nov

2008

Concert Pharmaceuticals, Inc.: Series C $37.0M

Posted in I - Series C, Q - 2Q08, R - NORTH EAST, X - HIV, X - MRSA, X - Pain, X - Schizophrenia

Concert Pharmaceuticals (Lexington, MA) development-stage pharmaceutical company focused on new chemical entities based upon modifications of validated drug molecules using deuterium chemistry, closed a $37M Series C financing. Participants include Adage Capital Management, SR One, Mediphase Venture Partners, Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, Flagship Ventures, [...]

Apr

2008

Adnavance Technologies, Inc.: Series B $3.6M

Posted in I - Series B, Q - 1Q08, R - INTERNATIONAL, X - Diagnostic, X - MRSA

Adnavance (Canada) developer of DNA detection molecular diagnostic tests for MRSA identification closed a $3.7M Series B financing. Participants include GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada.

to top of page...